CERO THERAPEUTICS HOLDINGS, INC.
No enriched coverage for $CERO in the last 7 days.
No SEC Form 4 filings for $CERO in the last 30 days.
CERO THERAPEUTICS HOLDINGS, INC. (CERO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 ea029846301ex4-1.htm SECOND AMENDED AND RESTATED NOTE (JULY 2026) Exhibit 4.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE R
Nasdaq said it will delist multiple issuers’ securities from the Nasdaq Stock Market, including CERo Therapeutics Holdings, Bowen Acquisition Corp, Graphjet Technology, Blue Hat Interactive Entertainment Technology, X3 Holdings Co, Captivision Inc, Actelis Networks, American Rebel Holdings, Reviva Pharmaceuticals, Alchemy Investments Acquisition Corp 1, Bitcoin Depot, Inotiv, GoHealth, Functional Brands, Sleep Number, Smart Digital Group, and REE Automotive. Most were suspended in 2025-2026 and
CERO THERAPEUTICS HOLDINGS, INC. (CERO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 ea029602201ex4-1.htm AMENDED AND RESTATED NOTE (JUNE 2026) Exhibit 4.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRA
Recent CERO coverage spans financial news and corporate actions.
The filing signals near-term dilution risk and financing overhang via a lender option to convert principal and accrued interest into CERO common stock.
Delisting risk is immediate and can impair liquidity, access to capital markets, and trading venue availability.
The filing discloses a new/updated dilutive financing structure (convertible note with a floor price), which can pressure equity via conversion over time.
The appointment of Eric Francois, a biotech finance veteran, to CERo Therapeutics' board signals strengthened strategic leadership, potentially accelerating clinical development and capital initiatives.
CERO exhibits neutral sentiment with minimal influence on overall market direction.
alphai scores every news story that mentions CERO with an AI model for sentiment and relevance, and aggregates insider trades from CERO THERAPEUTICS HOLDINGS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CERO THERAPEUTICS HOLDINGS, INC. (CERO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 ea029846301ex4-1.htm SECOND AMENDED AND RESTATED NOTE (JULY 2026) Exhibit 4.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE R
3 min readNasdaq said it will delist multiple issuers’ securities from the Nasdaq Stock Market, including CERo Therapeutics Holdings, Bowen Acquisition Corp, Graphjet Technology, Blue Hat Interactive Entertainment Technology, X3 Holdings Co, Captivision Inc, Actelis Networks, American Rebel Holdings, Reviva Pharmaceuticals, Alchemy Investments Acquisition Corp 1, Bitcoin Depot, Inotiv, GoHealth, Functional Brands, Sleep Number, Smart Digital Group, and REE Automotive. Most were suspended in 2025-2026 and
4 min readCERO THERAPEUTICS HOLDINGS, INC. (CERO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 ea029602201ex4-1.htm AMENDED AND RESTATED NOTE (JUNE 2026) Exhibit 4.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRA
4 min readCERo Therapeutics (OTCQB: CERO) has appointed Eric Francois, a biotechnology finance veteran with over 25 years of experience, to its Board of Directors. Francois previously served as CFO of SCYNEXIS, where he raised over $300 million, and also held senior banking positions. His expertise in capital raising, M&A, and business development is expected to significantly contribute to CERo's cellular immunotherapy programs and ongoing human clinical trials for cancer treatment.
2 min readU.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling more than 1% on Thursday. Following the market opening Thursday, the Dow traded up 0.03% to 47,644.08 while the NASDAQ fell 1.13% to 23,687.37. The S&P 500 also fell, dropping, 0.63% to 6,847.40.
4 min readTrading of the Company's shares of common stock on Nasdaq will be suspended at the open of trading on October ...
3 min readCompany completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance ...
3 min readStudy's Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval ...
2 min readThird patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort ...
3 min readThe most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
3 min read
